

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



August 12, 2021

Consolidated Financial Results for the Six Months Ended June 30, 2021 (under IFRS)

Company name: Kubota Pharmaceutical Holdings Co., Ltd.
 Listing: Tokyo Stock Exchange
 Securities code: 4596
 URL: <https://www.kubotaholdings.co.jp/en/>
 Representative: Ryo Kubota, Representative Executive Officer, Chairman, President and Chief Executive Officer
 Inquiries: Yumiko Hamanaka, Head of Corporate Planning Division
 Telephone: +81-3-6550-8928
 Scheduled date of the submission of quarterly securities report: August 12, 2021
 Scheduled date to commence dividend payments: –
 Preparation of supplementary material on quarterly financial results: Yes
 Holding of quarterly financial results presentation meeting: Yes (for institutional investors and analysts)

(Yen amounts are rounded to the nearest million, unless otherwise noted.)

1. Consolidated financial results for the six months ended June 30, 2021 (January 1, 2021 to June 30, 2021)

(1) Consolidated operating results (cumulative) (Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Net profit	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Six months ended								
June 30, 2021	–	–	(1,335)	–	(1,351)	–	(1,351)	–
June 30, 2020	38	–	(1,292)	–	(1,253)	–	(1,253)	–

	Profit attributable to owners of parent		Total comprehensive income		Basic earnings per share	Diluted earnings per share
	Millions of yen	%	Millions of yen	%	Yen	Yen
Six months ended						
June 30, 2021	(1,351)	–	(1,077)	–	(29.86)	(29.86)
June 30, 2020	(1,253)	–	(1,363)	–	(29.64)	(29.64)

(2) Consolidated financial position

	Total assets	Total shareholders' equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent
	Millions of yen	Millions of yen	Millions of yen	%
As of				
June 30, 2021	5,874	5,215	5,215	88.8
December 31, 2020	6,692	5,993	5,993	89.6

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
Fiscal year ended December 31, 2020	Yen –	Yen 0.00	Yen –	Yen 0.00	Yen 0.00
Fiscal year ending December 31, 2021	–	0.00			
Fiscal year ending December 31, 2021 (Forecast)			–	0.00	0.00

(Note) Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated earnings forecasts for the fiscal year ending December 31, 2021 (January 1, 2021 to December 31, 2021)

(Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Net profit	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Full year	10	(73.5)	(2,900)	–	(2,800)	–	(2,800)	–

	Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Yen
Full year	(2,800)	–	(62.84)

(Note) Revisions to the earnings forecasts most recently announced: None

*** Notes**

- (1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in scope of consolidation): None

Newly included: None

Excluded: None

- (2) Changes in accounting policies and changes in accounting estimates

(i) Changes in accounting policies required by IFRS: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

- (3) Number of issued shares (ordinary shares)

- (i) Total number of issued shares at end of the period (including treasury shares)

As of June 30, 2021	45,516,388 shares
As of December 31, 2020	44,558,588 shares

- (ii) Number of treasury shares at end of the period

As of June 30, 2021	70 shares
As of December 31, 2020	70 shares

- (iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

For the six months ended June 30, 2021	45,242,597 shares
For the six months ended June 30, 2020	42,295,790 shares

- * Quarterly financial results reports are exempt from quarterly reviews conducted by certified public accountants or an audit corporation.

- * Proper use of earnings forecasts, and other special items

(Cautions on forward-looking statements, etc.)

The earnings forecasts and other forward-looking statements contained in these materials are based on information currently available to Kubota Pharmaceutical Holdings Co., Ltd. (the “Company”) and on certain assumptions deemed to be reasonable by the Company. Actual business performance and other results may differ substantially due to various factors. Please refer to “1. Qualitative Information Regarding Financial Results for the Six Months ended June 30, 2021, (3) Explanation of consolidated earnings forecasts and other forward-looking statements” on page 4 of the attached materials for matters relating to earnings forecasts.

(Means of obtaining the presentation material on quarterly financial statements)

The Company is planning to hold a quarterly financial results presentation meeting (WEB conference, in Japanese only, recorded and available on the Company’s website at a later date) for institutional investors and analysts on August 24, 2021.

The Company also plans to post presentation materials (in English and Japanese) for the quarterly financial results and the recorded WEB conference available on the Company’s website.